Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis
- PMID: 31714440
- DOI: 10.1097/MPH.0000000000001654
Response to Denosumab in 2 Children With Recurrent Giant Cell Tumor of the Bone With Pulmonary Metastasis
Abstract
Giant cell tumor of the bone (GCTB) is an uncommon bone tumor, usually localized, and rarely presents at <20 years of age. Denosumab, a fully human monoclonal antibody against RANKL (receptor activator of nuclear factor κB ligand), is approved for the treatment of unresectable GCTB in skeletally mature individuals. We present a case series of 2 pediatric patients with recurrent GCTB with pulmonary metastasis, with clinical response to denosumab therapy.
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- Manfrini MPicci P, Manfrini M, Fabbri N, Gambarotti M, Vanel D. Giant cell tumor. Atlas of Musculoskeletal Tumors and Tumor like Lesions. Cham, Switzerland: Springer; 2014:91–94.
-
- Muheremu A, Niu X. Pulmonary metastasis for giant cell tumor of bones. World J Surg Oncol. 2014;12:261.
-
- Mamer R, Han-Soo K, Ji Y, et al. Surveillance for lung metastasis from giant cell tumor of the bone. J Surg Oncol. 2017;116:907–913.
-
- Viswanathan S, Jambhekar NA. Metastatic giant cell tumor of bone: are there associated factors and best treatment modalities? Clin Orthop Relat Res. 2010;468:827–833.
-
- Rosario M, Kim HS, Yun JY, et al. Surveillance for lung metastasis from giant cell tumor of bone. J Surg Oncol. 2017;116:907–913.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical